Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BJDX

BJDX - Bluejay Diagnostics, Inc. Stock Price, Fair Value and News

$0.82+0.06 (+7.89%)
Market Closed

Price Targets

BJDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BJDX Price Action

Last 7 days

17.1%

Last 30 days

20.6%

Last 90 days

-62.7%

Trailing 12 Months

-79.3%

BJDX RSI Chart

BJDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BJDX Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.22

Price/Sales (Trailing)

11.44

Price/Free Cashflow

-0.25

BJDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

BJDX Fundamentals

BJDX Revenue

Revenue (TTM)

249.0K

BJDX Earnings

Earnings (TTM)

-6.9M

Earnings Growth (Yr)

-7.81%

Earnings Growth (Qtr)

18.35%

BJDX Profitability

Return on Equity

-185.51%

Return on Assets

-140.09%

Free Cashflow Yield

-406.63%

BJDX Investor Care

Shares Dilution (1Y)

237.40%

Diluted EPS (TTM)

385.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20230000
20220133.0K191.0K249.0K
202100075.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Bluejay Diagnostics, Inc.

BJDX
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
 CEO
 WEBSITEbluejaydx.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES16

Bluejay Diagnostics, Inc. Frequently Asked Questions

BJDX is the stock ticker symbol of Bluejay Diagnostics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Bluejay Diagnostics, Inc. is 1.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BJDX's fair value in chart for subscribers.

The fair value guage provides a quick view whether BJDX is over valued or under valued. Whether Bluejay Diagnostics, Inc. is cheap or expensive depends on the assumptions which impact Bluejay Diagnostics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BJDX.

As of Wed Jan 28 2026, BJDX's PE ratio (Price to Earnings) is -0.22 and Price to Sales (PS) ratio is 11.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BJDX PE ratio will change depending on the future growth rate expectations of investors.